Abstracts

Previous | 1 | 2 | 3 | 4  Move down


  1. Kohútová B, Novák T, Kožený J, Tišanská L, Mravčíková K, Bednařík J, Höschl C. Comorbidities and quality of life in patients diagnosed with schizophrenia, depressive disorder, generalized anxiety disorder, and neuropathic pain: COSMOS project. Psychiatrie 23, 2019; S1:38
  2. Mutlu O, Cerit C, Pinterova N, Horacek J, Akar F, Palenicek T, Hoschl C, Vales K. Different effects of adipokinetic hormone/red pigment-concentrating hormone family of peptides in posttraumatic stress disorder model of rats. EUR NEUROPSYCHOPHARMACOLOGY, 29; 2019: S272-S273. DOI: 10.1016/j.euroneuro.2018.11.432
  3. Mutlu O, Kleteckova L, Horacek J, Holubova K, Palenicek T, Ulak G, Hoschl C, Vales K. Antidepressant effect of adipokinetic hormone/red pigment-concentrating hormone family of peptides in olfactory bulbectomy model of rats. EUR NEUROPSYCHOPHARMACOLOGY, 2019; 29: S271-S272. DOI: 10.1016/j.euroneuro.2018.11.431
  4. Mutlu O, Palenicek T, Pinterova N, Sichova K, Horacek J, Holubova K, Hoschl C, Stuchlik A, Erden F, Vales K. Effects of adipokinetic hormone/red pigment-concentrating hormone family of peptides on MK-801 induced schizophrenia models in rats. EUR NEUROPSYCHOPHARMACOLOGY 29; 2019: S264-S265. DOI: 10.1016/j.euroneuro.2018.11.421
  5. Höschl C. Schizophrenia and immune system. Proceedings of 40th Immunoanalytic days, Pilsen, 17-19 March 2019. Euroverlag, 2019, ISBN 978-80-7177-945-2
  6. Höschl C. Is ADHD historical novelty? Proceedings of 12th Annual Festival of Paediatric Case Reports. Žilina, Slovakia, 22-23 March 2019
  7. Khoo JP, Stein D, Ameringen MV, Hoschl C, et al. Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalised anxiety disorder. BIPOLAR DISORDERS, 2019, Vol. 21, S1: 135-135 Meeting Abstract: P-166

Previous | 1 | 2 | 3 | 4  Move up